Stephen J. Falk

机构：NIHR Bristol Cardiovascular Biomedical Research Unit · ORCID：0000-0001-6106-3062

发表论文 219 篇 · 总被引 25696 次 · h-index 58

代表论文

• Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial (2021 · The Lancet Oncology · 被引 787)
• Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial (2020 · The Lancet Oncology · 被引 250)
• Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer (2021 · JAMA Oncology · 被引 203)
• Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study (2020 · ˜The œLancet. Gastroenterology & hepatology · 被引 197)
• Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial (2023 · ˜The œLancet. Gastroenterology & hepatology · 被引 192)
• Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452). (2021 · Journal of Clinical Oncology · 被引 115)